Reported results
- Reported total revenue of $361.0 million for the third quarter of 2026, an increase of 36% compared to $265.2 million for the third quarter of 2025.
- Generated non-GAAP gross margin of 67% for the third quarter of 2026, compared to 66% for the third quarter of 2025.
- Reported Oncology revenue of $231.3 million and 117,000 oncology tests for the third quarter of 2026.
- Reported Screening revenue of $67.6 million and 83,000 Shield tests for the third quarter of 2026.
- Reported GAAP net loss of $124.4 million, or $0.93 per share, for the third quarter of 2026.
- Reported non-GAAP net loss of $38.8 million, or $0.29 per share, for the third quarter of 2026.
Guidance
- Full year 2026 revenue is expected to be in the range of $1.36 to $1.37 billion, representing growth of 38% to 40% compared to full year 2025.
- Oncology revenue is expected to grow approximately 30% and Oncology volume is expected to grow over 50%.
- Biopharma & Data revenue growth is expected to be in the low double-digit range.
- Screening revenue is expected to be in the range of $233 to $238 million, driven by Shield volume of 285,000 to 290,000 tests.
- Full year 2026 non-GAAP gross margin is expected to be 65%.
- Total non-GAAP operating expenses are expected to be in the range of $1.105 to $1.125 billion.
- Full-year free cash flow burn is expected to be $205 million to $220 million.
Price and volatility reaction
The stock moved -1.7% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -37.9 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 153.43 | 2026-11-05 |
| Close after release | 150.87 | 2026-11-06 |
| Realised move | -1.7% | close to close |
| 30d ATM IV change | -37.9 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
